** Brokerage RBC Capital Markets raises PT on drugmaker Vertex Pharmaceutical VRTX.O to $420 from $408
** Brokerage suggests VRTX's cystic fibrosis treatment, Alyftrek, could be off to a "good start"
** The FDA approved VRTX's next-generation treatment for the genetic disease that affects lungs and other organs, in December 2024, after it showed non-inferiority to Vertex's Trikafta
** RBC says declines in Trifakta prescriptions leave open a good possibility that initial conversion to Alyftrek may be faster than expected, likely outpacing Street's $79 million sales expectations for Alyftrek in Q1
** Twenty-one of 33 brokerages rate the stock "buy" or higher, 12 "hold"; their median PT is $502.23, according to the data compiled by LSEG
** As of last close, VRTX has risen 16% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。